|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Increased expression and amplification of mdr1 sequences were also found in multidrug-resistant sublines of human leukemia and ovarian carcinoma cells.
|
3457471 |
1986 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Treatment of leukaemia cells with 3p-siRNA-MDR1 down-regulated MDR1 expression, reduced-drug resistance and induced immune and pro-apoptotic effects in drug-resistant HL-60/Adr and K562/Adr human leukaemia cell lines.
|
28380403 |
2017 |
|
leukemia
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
In this review, we cover the current information and postulate that epigenetic modification of MDR1 chromatin influences gene transcription in leukaemia.
|
14567978 |
2003 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These findings indicate that siRNA specifically and efficiently interferes with the expression of mdr1 and could be used as a molecularly defined therapeutic approach for MDR in the treatment of leukemia.
|
15375375 |
2004 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, there is evidence that the pattern of MDR1 expression observed in leukemias reflects the distribution of MDR1 in normal hematopoiesis.
|
7540457 |
1995 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this report, we describe a novel G571A variant of MDR1 detected in 6.4% of leukemia patients.
|
18723777 |
2008 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The MDR1 expression rate was significantly correlated with factors such as a history of preceding chemotherapy, elder age of the patient, and certain disease types (eg, leukemia progressed from myelodysplastic syndrome).
|
10695666 |
2000 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Retroviral vector transduction of human leukemia cell lines expressing MDR1 was accomplished by co-culturing these with virus producer cells.
|
10362143 |
1999 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Expression of the human multidrug resistance 1 gene (MDR1), which encodes the P-glycoprotein transmembrane efflux pump, has been associated with treatment failure of some leukemias, primarily acute myeloid leukemia (AML).
|
10360380 |
1999 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment of multidrug resistant (MDR1) murine leukemia with P-glycoprotein substrates accelerates the course of the disease.
|
10581184 |
1999 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
White blood cells from a total of 19 patients diagnosed as having acute lymphoblastic (ALL) or acute myeloid (AML) leukaemia were analysed (36 samples) for amplification and expression of the mdr1 and mdr3 genes.
|
8574159 |
1995 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The association between the MDR1 G2677T polymorphism and leukemia risk was conducted by odds ratios (ORs) and 95% confidence intervals (95% CI).
|
24142546 |
2014 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression of 10 U or more of mdr1 was found in 6 of 31 (19%) leukemias at diagnosis, versus 5 of 10 (50%) after relapse from therapy, P = .06.
|
1859877 |
1991 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Calculating the mean values we found: (i) a distinctly lower mdr1 gene expression in primary ALL and first relapses compared to bone marrow from healthy donors, (ii) no change in mdr1 and mrp, but a decreased topoisomerase II alpha gene expression in first relapses of ALL compared to the primary leukaemia, and (iii) increased mdr1 and mrp levels combined to decreased topoisomerase II alpha levels in recurrent relapses of ALL showing significant correlations (mdr1/mrp: rs = +0.6833, P < 0.05; mdr1/topoII alpha: rs = -0.6727, P < 0.05).
|
7873386 |
1995 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The multidrug resistance gene, MDR1, is one of the genes responsible for resistance to chemotherapy in the treatment of leukaemia and other cancers.
|
17909680 |
2007 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We examined the expression of the mdr1 gene in 90 human tumor cell lines of which 79 were derived from leukemia or lymphoma samples.
|
8099136 |
1993 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the tumor-bearing nude mice, anti-tumor drugs vincristine, daunorubicin (DNR), STI571, and STI571 plus VCR for the treatment of mdr1 and bcr/abl double positive leukemia were studied respectively.
|
16780770 |
2006 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this present study we have measured RNA levels of mdr1 and gst-pi in primary human breast tumour biopsies prior to chemotherapy and from tumours which have different inherent responses to doxorubicin treatment, including colon, head and neck squamous cell carcinomas and myeloid leukaemias.
|
1970934 |
1990 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.
|
12609962 |
2003 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
High mdr1- and mrp-, but low topoisomerase II alpha-gene expression in B-cell chronic lymphocytic leukaemias.
|
7954350 |
1994 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bortezomib is a promising potential therapy for acute leukemia, especially mdr1 drug-resistant leukemia.
|
22145750 |
2012 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Sequential emergence of MRP- and MDR1-gene over-expression as well as MDR1-gene translocation in homoharringtonine-selected K562 human leukemia cell lines.
|
8575859 |
1996 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings suggest that MDR1-AS is useful to overcome multidrug resistance in the treatment of leukemia.
|
9558371 |
1998 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, expression of mdr1 RNA is common in acute untreated leukaemia.
|
1380280 |
1992 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
P-glycoprotein (P-gp)/multi-drug resistance 1 (MDR1) gene is recognized to be, at least in part, responsible for the refractoriness to chemotherapy of leukemia.
|
11734301 |
2002 |